XML 74 R67.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details) - United Therapeutics Corporation - Collaboration and License Agreement $ in Millions | 1 Months Ended
--- | ---
Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |
Total anticipated cash flows | $ 722.3 | [1]
Manufacturing Services |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |
Total anticipated cash flows | 722.3 |
Manufacturing Services and Product Sales |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |
Allocated transaction price | 220.8 |
Manufacturing Services and Product Sales | Transaction Price For The Contractual Obligations |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |
Total anticipated cash flows | 120.0 |
Next-Gen R&D Services | Transaction Price For The Performance Obligations |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |
Total anticipated cash flows | $ 602.3 |
[1] | The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.

X
- Definition Allocated transaction price. + References No definition available. + Details
Name: | mnkd_AllocatedTransactionPrice
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue remaining performance obligation anticipated cash flow. + References No definition available. + Details
Name: | mnkd_RevenueRemainingPerformanceObligationAnticipatedCashFlow
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_ManufacturingServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_ManufacturingServicesAndProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=mnkd_TransactionPriceForTheContractualObligationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_NextGenResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=mnkd_TransactionPriceForThePerformanceObligationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |